tiprankstipranks
Gyre Therapeutics: Annual Financial Results and Future Outlook
Company Announcements

Gyre Therapeutics: Annual Financial Results and Future Outlook

Gyre Therapeutics (GYRE) has released an update.

GNI Group Ltd. released its financial results for the year ended December 31, 2023, on February 14, 2024, spotlighting the performance of its subsidiary, Gyre Therapeutics. The report also highlighted key future events, including the expected submission of an Investigational New Drug application and the completion of Phase 3 clinical trials for Hydronidone in China. Additionally, Gyre Therapeutics settled legal disputes regarding its business combination agreement by agreeing to pay attorney’s fees, thereby avoiding further litigation costs.

For further insights into GYRE stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskGyre Therapeutics Seeks Compliance Amid Board Reshuffle
GlobeNewswireGyre Therapeutics Announces China’s NMPA Approval of Avatrombopag Maleate Tablets for the Treatment of CLD-Associated Thrombocytopenia
TheFlyNMPA approves Gyre’s avatrombopag maleate tablets for TP associated with CLD
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Optimize your mobile reading experience. Download the TipRanks App today!